SLS
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEOs Fox Appearance
Article Summary
HOLD- SELLAS Life Sciences (NASDAQ: SLSL) rose 0.4% overnight after a new acute myeloid leukemia (AML) study published in Haematologica showed median overall survival of 19 months among patients receiving venetoclax compared with venetocin for first-time AML patients, with median overall life expectancy of 16.6 months compared with 12.5 months for patients receiving lower-intensity veneticlax.
- The study examined 362 adults with newly diagnosed AML who achieved a first complete remission but did not undergo stem cell transplantation and found median overall mortality was 19 months across the full group.
- The data showed survival averages fell sharply among older, adverse-risk and MRD-positive patients, potentially easing concerns that Regal's control arm will outperform expectations, though the study did not evaluate GPS and focused on patients in first remission making it an indirect benchmark rather than evidence Regal will succeed.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 122.9% | 20% | 100.0 ptsMassive Upside (122.9%) - Target: $27.50 vs Current: $12.34 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -22.3% | 15% | 40.0 ptsMild Pullback (-22.3%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SLS
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
- SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.